Suppr超能文献

空间突触连接是少突胶质细胞瘤演变和复发的基础。

Spatial synaptic connectivity underlies oligodendroglioma evolution and recurrence.

作者信息

Raleigh David, Mirchia Kanish, Oten Sena, Picart Thiebaud, Nguyen Minh, Ambati Vardhaan, Vasudevan Harish, Young Jacob, Taylor Jennie, Krishna Saritha, Brang David, Phillips Joanna, Perry Arie, Berger Mitchel, Chang Susan, de Groot John, Hervey-Jumper Shawn

出版信息

Res Sq. 2025 Apr 4:rs.3.rs-6299872. doi: 10.21203/rs.3.rs-6299872/v1.

Abstract

Oligodendrogliomas are initially slow-growing brain tumors that are prone to malignant transformation despite surgery and cytotoxic therapy. Understanding of oligodendroglioma evolution and new treatments for patients have been encumbered by a paucity of patient-matched newly diagnosed and recurrent tumor samples for multiplatform analyses, and by a lack of preclinical models for interrogation of therapeutic vulnerabilities that drive oligodendroglioma growth. Here we integrate spatial and functional analyses of tumor samples and patient-derived organoid co-cultures to show that synaptic connectivity is a hallmark of oligodendroglioma evolution and recurrence. We find that patient-matched recurrent oligodendrogliomas are enriched in synaptic gene expression programs irrespective of previous therapy or histologic grade. Analyses of spatial, single-cell, and clinical data reveal epigenetic misactivation of synaptic genes that are concentrated in regions of cortical infiltration and can be used to predict eventual oligodendroglioma recurrence. To translate these findings to patients, we show that local field potentials from tumor-infiltrated cortex at the time of resection and neuronal hyperexcitability and synchrony in patient-derived organoid co-cultures are associated with oligodendroglioma proliferation and recurrence. In preclinical models, we find that neurophysiologic drugs block oligodendroglioma growth and pathologic electrophysiology. These results elucidate mechanisms underlying oligodendroglioma evolution from an indolent tumor to a fatal disease and shed light on new biomarkers and new treatments for patients.

摘要

少突胶质细胞瘤最初是生长缓慢的脑肿瘤,尽管进行了手术和细胞毒性治疗,但仍易于发生恶性转化。由于缺乏用于多平台分析的患者匹配的新诊断和复发性肿瘤样本,以及缺乏用于探究驱动少突胶质细胞瘤生长的治疗脆弱性的临床前模型,对少突胶质细胞瘤演变的理解和针对患者的新治疗方法受到了阻碍。在这里,我们整合了肿瘤样本和患者来源的类器官共培养物的空间和功能分析,以表明突触连接是少突胶质细胞瘤演变和复发的标志。我们发现,无论先前的治疗或组织学分级如何,患者匹配的复发性少突胶质细胞瘤在突触基因表达程序中都很丰富。对空间、单细胞和临床数据的分析揭示了突触基因的表观遗传失活,这些基因集中在皮质浸润区域,可用于预测少突胶质细胞瘤最终的复发。为了将这些发现应用于患者,我们表明,切除时肿瘤浸润皮质的局部场电位以及患者来源的类器官共培养物中的神经元过度兴奋和同步性与少突胶质细胞瘤的增殖和复发有关。在临床前模型中,我们发现神经生理药物可阻断少突胶质细胞瘤的生长和病理性电生理。这些结果阐明了少突胶质细胞瘤从惰性肿瘤演变为致命疾病的潜在机制,并为患者的新生物标志物和新治疗方法提供了线索。

相似文献

3
Genomic alterations of oligodendrogliomas at distant recurrence.远处复发性少突胶质细胞瘤的基因组改变。
Cancer Med. 2023 Aug;12(16):17171-17183. doi: 10.1002/cam4.6327. Epub 2023 Aug 2.
5
Oligodendroglioma: pathology and molecular biology.少突胶质细胞瘤:病理学与分子生物学
Surg Neurol. 2002 Aug;58(2):111-7; discussion 117. doi: 10.1016/s0090-3019(02)00751-6.
7
Current diagnosis and treatment of oligodendroglioma.少突胶质细胞瘤的当前诊断与治疗
Neurosurg Focus. 2002 Feb 15;12(2):E2. doi: 10.3171/foc.2002.12.2.3.
9
Oligodendrogliomas.少突胶质细胞瘤
Neurol Clin. 1995 Nov;13(4):861-73.

本文引用的文献

8
A prognostic neural epigenetic signature in high-grade glioma.高级别胶质瘤中的预后神经表观遗传特征。
Nat Med. 2024 Jun;30(6):1622-1635. doi: 10.1038/s41591-024-02969-w. Epub 2024 May 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验